Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

An innovative approach in the detection of Toxocara canis excretory/secretory antigens using specific nanobodies.

Morales-Yanez FJ, Sariego I, Vincke C, Hassanzadeh-Ghassabeh G, Polman K, Muyldermans S.

Int J Parasitol. 2019 Jul;49(8):635-645. doi: 10.1016/j.ijpara.2019.03.004. Epub 2019 May 29.

2.

In planta expression of nanobody-based designer chicken antibodies targeting Campylobacter.

Vanmarsenille C, Elseviers J, Yvanoff C, Hassanzadeh-Ghassabeh G, Garcia Rodriguez G, Martens E, Depicker A, Martel A, Haesebrouck F, Pasmans F, Hernalsteens JP, De Greve H.

PLoS One. 2018 Sep 27;13(9):e0204222. doi: 10.1371/journal.pone.0204222. eCollection 2018.

3.

Nanobodies targeting conserved epitopes on the major outer membrane protein of Campylobacter as potential tools for control of Campylobacter colonization.

Vanmarsenille C, Díaz Del Olmo I, Elseviers J, Hassanzadeh Ghassabeh G, Moonens K, Vertommen D, Martel A, Haesebrouck F, Pasmans F, Hernalsteens JP, De Greve H.

Vet Res. 2017 Dec 8;48(1):86. doi: 10.1186/s13567-017-0491-9.

4.

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.

Kromann-Hansen T, Louise Lange E, Peter Sørensen H, Hassanzadeh-Ghassabeh G, Huang M, Jensen JK, Muyldermans S, Declerck PJ, Komives EA, Andreasen PA.

Sci Rep. 2017 Jun 13;7(1):3385. doi: 10.1038/s41598-017-03457-7.

5.

Identification and characterization of Nanobodies targeting the EphA4 receptor.

Schoonaert L, Rué L, Roucourt B, Timmers M, Little S, Chávez-Gutiérrez L, Dewilde M, Joyce P, Curnock A, Weber P, Haustraete J, Hassanzadeh-Ghassabeh G, De Strooper B, Van Den Bosch L, Van Damme P, Lemmens R, Robberecht W.

J Biol Chem. 2017 Jul 7;292(27):11452-11465. doi: 10.1074/jbc.M116.774141. Epub 2017 May 19.

6.

Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis.

Arezumand R, Mahdian R, Zeinali S, Hassanzadeh-Ghassabeh G, Mansouri K, Khanahmad H, Namvar-Asl N, Rahimi H, Behdani M, Cohan RA, Eavazalipour M, Ramazani A, Muyldermans S.

Mol Immunol. 2016 Oct;78:183-192. doi: 10.1016/j.molimm.2016.09.012. Epub 2016 Sep 17.

PMID:
27648860
7.

Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1.

Zhou X, Hendrickx ML, Hassanzadeh-Ghassabeh G, Muyldermans S, Declerck PJ.

Thromb Haemost. 2016 Nov 30;116(6):1032-1040. Epub 2016 Sep 8.

PMID:
27604413
8.

A nanobody modulates the p53 transcriptional program without perturbing its functional architecture.

Bethuyne J, De Gieter S, Zwaenepoel O, Garcia-Pino A, Durinck K, Verhelle A, Hassanzadeh-Ghassabeh G, Speleman F, Loris R, Gettemans J.

Nucleic Acids Res. 2014 Nov 10;42(20):12928-38. doi: 10.1093/nar/gku962. Epub 2014 Oct 16.

9.

Interactions between metal-binding domains modulate intracellular targeting of Cu(I)-ATPase ATP7B, as revealed by nanobody binding.

Huang Y, Nokhrin S, Hassanzadeh-Ghassabeh G, Yu CH, Yang H, Barry AN, Tonelli M, Markley JL, Muyldermans S, Dmitriev OY, Lutsenko S.

J Biol Chem. 2014 Nov 21;289(47):32682-93. doi: 10.1074/jbc.M114.580845. Epub 2014 Sep 24.

10.

A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation.

Yardehnavi N, Behdani M, Bagheri KP, Mahmoodzadeh A, Khanahmad H, Shahbazzadeh D, Habibi-Anbouhi M, Hassanzadeh Ghassabeh G, Muyldermans S.

FASEB J. 2014 Sep;28(9):4004-14. doi: 10.1096/fj.13-247478. Epub 2014 Jun 2.

11.

Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization.

Van Audenhove I, Boucherie C, Pieters L, Zwaenepoel O, Vanloo B, Martens E, Verbrugge C, Hassanzadeh-Ghassabeh G, Vandekerckhove J, Cornelissen M, De Ganck A, Gettemans J.

FASEB J. 2014 Apr;28(4):1805-18. doi: 10.1096/fj.13-242537. Epub 2014 Jan 10.

PMID:
24414419
12.

In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.

Hendrickx ML, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ.

Thromb Haemost. 2014 May 5;111(5):824-32. doi: 10.1160/TH13-08-0645. Epub 2014 Jan 9.

PMID:
24402608
13.

Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application.

Hendrickx ML, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ.

J Thromb Haemost. 2014 Feb;12(2):229-36. doi: 10.1111/jth.12473.

14.

A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis.

Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, De Wever O, Vanloo B, Van Troys M, Lambein K, Boucherie C, Martens E, Zwaenepoel O, Hassanzadeh-Ghassabeh G, Vandekerckhove J, Gevaert K, Fernández LÁ, Sanders NN, Gettemans J.

Breast Cancer Res. 2013 Dec 13;15(6):R116. doi: 10.1186/bcr3585.

15.

The genome-wide binding profile of the Sulfolobus solfataricus transcription factor Ss-LrpB shows binding events beyond direct transcription regulation.

Nguyen-Duc T, van Oeffelen L, Song N, Hassanzadeh-Ghassabeh G, Muyldermans S, Charlier D, Peeters E.

BMC Genomics. 2013 Nov 25;14:828. doi: 10.1186/1471-2164-14-828.

16.

Nanobodies and their potential applications.

Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S.

Nanomedicine (Lond). 2013 Jun;8(6):1013-26. doi: 10.2217/nnm.13.86.

17.

V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays.

Habib I, Smolarek D, Hattab C, Grodecka M, Hassanzadeh-Ghassabeh G, Muyldermans S, Sagan S, Gutiérrez C, Laperche S, Le-Van-Kim C, Aronovicz YC, Wasniowska K, Gangnard S, Bertrand O.

Anal Biochem. 2013 Jul 1;438(1):82-9. doi: 10.1016/j.ab.2013.03.020. Epub 2013 Mar 26.

PMID:
23541519
18.

Nanobody(R)-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites.

Nguyen-Duc T, Peeters E, Muyldermans S, Charlier D, Hassanzadeh-Ghassabeh G.

Nucleic Acids Res. 2013 Mar 1;41(5):e59. doi: 10.1093/nar/gks1342. Epub 2012 Dec 28.

19.

Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.

Behdani M, Zeinali S, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A, Seyed N, Moazami-Godarzi R, Baniahmad F, Habibi-Anbouhi M, Hassanzadeh-Ghassabeh G, Muyldermans S.

N Biotechnol. 2013 Jan 25;30(2):205-9. doi: 10.1016/j.nbt.2012.09.002. Epub 2012 Sep 29.

PMID:
23031816
20.

Generation of single domain antibody fragments derived from camelids and generation of manifold constructs.

Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G, Muyldermans S.

Methods Mol Biol. 2012;907:145-76. doi: 10.1007/978-1-61779-974-7_8.

PMID:
22907350
21.

Nanobody-based chromatin immunoprecipitation.

Duc TN, Hassanzadeh-Ghassabeh G, Saerens D, Peeters E, Charlier D, Muyldermans S.

Methods Mol Biol. 2012;911:491-505. doi: 10.1007/978-1-61779-968-6_31.

PMID:
22886272
22.

Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.

Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghe S, Habibi Anbouhi M, Hassanzadeh-Ghassabeh G, Muyldermans S.

Mol Immunol. 2012 Feb;50(1-2):35-41. doi: 10.1016/j.molimm.2011.11.013. Epub 2011 Dec 29.

PMID:
22208996
23.

Generation of anti-infectome/anti-proteome nanobodies.

Hassanzadeh-Ghassabeh G, Saerens D, Muyldermans S.

Methods Mol Biol. 2011;790:239-59. doi: 10.1007/978-1-61779-319-6_19.

PMID:
21948420
24.

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation.

Hendrickx ML, DE Winter A, Buelens K, Compernolle G, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ.

J Thromb Haemost. 2011 Nov;9(11):2268-77. doi: 10.1111/j.1538-7836.2011.04495.x.

25.

A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads.

Thys B, Saerens D, Schotte L, De Bleeser G, Muyldermans S, Hassanzadeh-Ghassabeh G, Rombaut B.

J Virol Methods. 2011 May;173(2):300-5. doi: 10.1016/j.jviromet.2011.02.023. Epub 2011 Mar 1.

PMID:
21371506
26.

In vitro antiviral activity of single domain antibody fragments against poliovirus.

Thys B, Schotte L, Muyldermans S, Wernery U, Hassanzadeh-Ghassabeh G, Rombaut B.

Antiviral Res. 2010 Aug;87(2):257-64. doi: 10.1016/j.antiviral.2010.05.012. Epub 2010 Jun 8.

PMID:
20566349
27.

A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Smolarek D, Hattab C, Hassanzadeh-Ghassabeh G, Cochet S, Gutiérrez C, de Brevern AG, Udomsangpetch R, Picot J, Grodecka M, Wasniowska K, Muyldermans S, Colin Y, Le Van Kim C, Czerwinski M, Bertrand O.

Cell Mol Life Sci. 2010 Oct;67(19):3371-87. doi: 10.1007/s00018-010-0387-6. Epub 2010 May 11.

28.

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor.

Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ.

J Thromb Haemost. 2010 Jun;8(6):1302-12. doi: 10.1111/j.1538-7836.2010.03816.x. Epub 2010 Feb 17.

29.

Camelid immunoglobulins and nanobody technology.

Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, Rothbauer U, Stijlemans B, Tillib S, Wernery U, Wyns L, Hassanzadeh-Ghassabeh G, Saerens D.

Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):178-83. doi: 10.1016/j.vetimm.2008.10.299. Epub 2008 Oct 17.

PMID:
19026455
30.

Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.

Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P.

Immunobiology. 2006;211(6-8):487-501. Epub 2006 Jul 21. Review.

PMID:
16920488
31.

Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer.

Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Hassanzadeh Ghassabeh G, Raes G, De Baetselier P.

Blood. 2006 Jul 15;108(2):525-35. Epub 2006 Mar 9.

32.

Alternatively activated macrophages during parasite infections.

Noël W, Raes G, Hassanzadeh Ghassabeh G, De Baetselier P, Beschin A.

Trends Parasitol. 2004 Mar;20(3):126-33. Review.

PMID:
15036034
33.

Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.

Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5778-82. Epub 2003 May 5.

Supplemental Content

Loading ...
Support Center